Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency

Summary

To Evaluate the safety and efficacy of PEG Somatropin in the treatment of children with growth hormone deficiency, as well as to study the dosage of PEG Somatropin.

Conditions

• Growth Hormone Deficiency

Interventions

BIOLOGICAL

PEG-somatropin

30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.

Sponsors & Collaborators

• Beijing Children's Hospital

  collaborator OTHER

• Tianjin Medical University General Hospital

  collaborator OTHER

• Peking University Third Hospital

  collaborator OTHER

• China-Japan Friendship Hospital

  collaborator OTHER

• Dalian Children's Hospital

  collaborator OTHER

• Xian Children's Hospital

  collaborator OTHER_GOV

• Wuhan Children's Hospital

  collaborator OTHER

• Fuzhou Children s Hospital

  collaborator UNKNOWN

• Anhui Provincial Children's Hospital

  collaborator OTHER

• Hunan Children's Hospital

  collaborator OTHER_GOV

• Shenzhen Children's Hospital

  collaborator OTHER_GOV

• Children's Hospital of Hebei Province

  collaborator OTHER

• Second Affiliated Hospital of Xi'an Jiaotong University

  collaborator OTHER

• Zhengzhou Children's Hospital, China

  collaborator OTHER

• Children's Hospital of Soochow University

  collaborator OTHER

• Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region

  collaborator OTHER

• First Affiliated Hospital of Kunming Medical University

  collaborator OTHER

• Kunming Children's Hospital

  collaborator OTHER

• The First People's Hospital of Yunnan

  collaborator OTHER

• Xuzhou Children's Hopspital

  collaborator UNKNOWN

• Henan Provincial People's Hospital

  collaborator OTHER

• The First Affiliated Hospital of Henan University of Traditional Chinese Medicine

  collaborator OTHER

• First Affiliated Hospital of Harbin Medical University

  collaborator OTHER

• The Second Hospital of Hebei Medical University

  collaborator OTHER

• Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

  collaborator OTHER

• Union Hospital of Tongji Medical College of HUST

  collaborator UNKNOWN

• Wuxi Women's & Children's Hospital

  collaborator OTHER

• The Second Affiliated Hospital of Kunming Medical University

  collaborator OTHER

• Nanjing Children's Hospital

  collaborator OTHER

• Changchun GeneScience Pharmaceutical Co., Ltd.

  lead INDUSTRY

Principal Investigators

• Chunxiu Gong · Beijing Children's Hospital

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

3 Years

Max Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2015-01-31

Primary Completion

2017-08-31

Countries

• China

Study Locations